
Ambulatory Chronic Kidney Disease (CKD) Management in Alberta Using Connect Care
Specialty Medicine (Focused Systems)
2025-04-23 – Present
Chronic Kidney Disease (CKD) affects one in ten Canadians, yet a significant gap remains between international treatment guidelines and real-world clinical practice. For Albertans, this gap in guideline-concordant care translates into a substantial health system burden, increasing the risk of ED visits, acute kidney injuries, and major cardiovascular events. Because untreated CKD often progresses to costly interventions such as dialysis and transplantation, understanding current management patterns is critical for provincial healthcare stability. In collaboration with Dr. Tyrone Harrison and nephrology specialists, this project utilizes a comprehensive analysis of Connect Care, Drug Optimization, Sustainability, and Evaluation (DOSE), and the pharmaceutical information network (PIN) administrative databases to establish a baseline for evidence-based care. The study specifically examines healthcare utilization and prescription patterns for key therapeutic classes—including sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon like peptide 1 (GLP-1) receptor agonists, and ns-MRAs—to evaluate their association with patient outcomes.
Over the past year, the project has transitioned from design to execution. With cohort identification and data extraction complete, the project has begun a high-level analysis of CKD care trajectories. These findings will provide the foundational evidence required to drive future QI initiatives and strategic resource allocation across Alberta’s healthcare landscape
This work will establish baseline insights into CKD management across Alberta, identifying gaps in guideline-concordant care and informing future quality improvement and research initiatives.